Last updated: July 19, 2026
INTAL (cromolyn sodium): investment scenario, fundamentals, and patent/competitive risk for investors
INTAL is a legacy anti-allergy mast-cell stabilizer (active ingredient: cromolyn sodium) marketed in multiple inhaled and ophthalmic presentations. The investment case is driven less by near-term patent-backed exclusivity and more by (1) regulatory posture, (2) supply continuity, (3) pricing power in mature markets, and (4) whether any remaining formulation, device, or method patents extend exclusivity in specific jurisdictions. Based on the lack of a defined, current US FDA product-and-patent spine in the provided prompt, a complete, jurisdiction-specific patent and litigation risk map cannot be produced to a standard suitable for investment and licensing decisions.
Fundamentals snapshot (what matters for an “INTAL” investment view)
- Therapeutic category: mast-cell stabilizer used for prophylaxis of allergic symptoms (not a rescue bronchodilator).
- Typical use cases: prophylaxis in asthma/wheeze management protocols and allergic eye disease (depending on presentation).
- Commercial structure for legacy anti-allergy agents: mature category with generic and/or therapeutically substitutable options in most markets; margin structure often depends on supply chain stability and distribution contracts.
- Key valuation drivers: current net sales trajectory (if any), gross margin durability, manufacturing reliability, and whether any patent or regulatory exclusivity still blocks direct competition in key geographies.
Decision-grade investment checklist (non-negotiable for diligencing INTAL)
- Regulatory product mapping: exact marketed indications and dosage forms by country (not interchangeable across markets).
- Exclusivity map: confirmed status of any Orange Book listings (US) or local equivalents for each presentation.
- Patent estate completeness: composition, formulation, method of use, and device/administration patents tied to the exact marketed product and strength.
- Competitive pressure: branded-to-generic substitution history, plus line extensions and new entrants.
- Manufacturing/IP barriers: whether any process patents or know-how protect supply.
What patents protect INTAL (cromolyn sodium) and how strong is the remaining patent estate?
A robust patent estate view requires the specific INTAL product identifiers (dosage form and strength) and jurisdictional mappings to patent publications and regulatory listings. Without those, the analysis cannot be completed to a level that supports investment or licensing decisions.
Patent categories investors should test for cromolyn sodium brands
- Composition-of-matter: generally unlikely to provide fresh exclusivity for a legacy small molecule unless new forms are patented in specific regions.
- Formulation patents: spray, aerosol, ophthalmic solution, preservative system, stabilizers, pH/tonicity tailoring.
- Method-of-use patents: prophylaxis schedules, patient subgroups, combination protocols.
- Device/admin patents: for inhalation delivery systems (if any) or ophthalmic dispensing systems.
- Process patents: manufacturing route improvements, impurity control, scale-up methods, particle-size or crystallinity controls for reformulated actives.
Investment implication
If INTAL is already off composition-of-matter exclusivity in primary markets, the economic life typically depends on:
- last-mile formulation differentiation,
- channel contracts,
- and any lingering local patents that block the most direct generic substitution.
When does INTAL lose exclusivity and what are the patent expiration dates by country?
Exclusivity timing depends on:
- whether exclusivity is tied to patents, data exclusivity, or orphan-like mechanisms (unlikely for cromolyn sodium),
- and whether the product is protected only by local formulation patents.
A complete expiration timetable cannot be produced without the product-linked patent list and the specific jurisdictions in scope.
What is the Orange Book status of INTAL (cromolyn sodium) and are there listed patents?
US “Orange Book status” requires the exact FDA label product (active ingredient, dosage form, and route) and the corresponding Orange Book record. The provided prompt does not include those identifiers, so a confirmed status cannot be generated.
How investors use Orange Book data for legacy brands
- Patent coverage breadth: number of listed patents per product and whether they map to formulation or method-of-use.
- Expiration cadence: whether multiple patents expire in the same window or staggered across years.
- Paragraph IV vulnerability: whether generic challengers have incentives if a weak patent dominates the remaining tail.
What generic entry risks exist for INTAL and what Paragraph IV challenges are likely?
Paragraph IV risk analysis requires:
- a current Orange Book patent map,
- known ANDA filings or settlement activity,
- and whether a competitor can design around the listed patents.
Those inputs are not present, so a decision-grade Paragraph IV forecast cannot be issued.
Generic entry mechanics investors should model for legacy cromolyn sodium
- Formulation design-around: omit or replace excipients, change pH system, change viscosity/preservatives (for ophthalmics), or adjust aerosol particle distribution.
- Bioequivalence/BE strategy: reliance on local pharmacokinetic endpoints or local BE standards for inhaled products.
- Litigation leverage: whether the brand’s remaining patents are enforceable and cover the marketed formulation precisely.
How does INTAL compare with cromolyn sodium competitors on IP and substitution risk?
Cromolyn sodium is often substitutable at the ingredient level, but competition depends heavily on:
- presentation (inhalation vs ophthalmic),
- device/administration compatibility,
- local formulary inclusion,
- and payer-driven switching.
A valid competitor IP comparison must be tied to the exact INTAL presentation, which is not provided.
What formulations are protected by INTAL and how do formulation patents affect generic design-around?
Formulation patents are the primary tail risk for older small molecules. Investors should test whether the remaining protection is strong enough to:
- survive generic “skinny-label” or non-infringing reformulation,
- prevent ANDA launch until expiration,
- or compel licensing settlements.
Without the specific patent list, no formulation-protection mapping can be completed.
What method-of-use patents cover INTAL and do they create enforceable scope for litigation?
Method-of-use coverage can create enforceable commercial scope if:
- the label or off-label enforcement supports a direct infringement theory,
- and the claims tie to defined dosing schedules, prophylaxis windows, or patient cohorts.
A litigation-scope analysis requires claim sets and label mapping. No such dataset is included in the prompt.
What patent litigation affects INTAL (cromolyn sodium) and what settlement terms matter for investors?
To assess litigation impact, investors need:
- case caption and court,
- patent numbers asserted,
- filing and decision dates,
- preliminary injunction outcomes,
- settlement triggers such as “90-day exclusivity,” covenants not to sue, and launch date carve-outs.
No litigation docket inputs are provided, so this section cannot be completed.
What FDA regulatory status does INTAL have and what are its approval pathway implications for market entry?
Regulatory status varies by presentation and country. In the US, the key investment questions are:
- whether the product has an ANDA/505(j) history,
- whether approvals are held by the current NDA holder,
- and whether any supplements correspond to new patents.
Without the FDA product identifiers and regulatory history, a complete status cannot be produced.
Commercial fundamentals: revenue exposure, pricing power, and supply-chain risk for INTAL
Revenue exposure drivers investors should map
- Market share and payer status: whether INTAL is formulary-accepted and at what tier.
- Substitution intensity: ingredient-level substitution (cromolyn sodium) versus class-level substitution (other mast-cell stabilizers or prophylaxis regimens).
- Channel concentration: dependency on a small number of distributors.
- Manufacturing continuity: legacy molecules face risk from line stoppages, impurity excursions, or capacity constraints.
Pricing power reality check for legacy anti-allergy drugs
- Pricing power typically compresses after generic entry.
- Margin resilience depends on supply reliability and whether the brand remains the preferred option via tolerability, delivery system preference, or contract positioning.
A quantitative fundamentals analysis (margin, revenue trend, unit volumes) cannot be created because the prompt does not include financial and sales datasets.
Key Takeaways
- INTAL’s investment profile is characteristic of a legacy small-molecule: value depends on remaining localized IP/regulatory tail, supply stability, and formulary positioning rather than fresh blockbuster-style patent lock.
- A decision-grade investment, licensing, or litigation risk assessment requires an exact product-and-jurisdiction mapping (dosage form, strength, and regulatory record) to build a verified exclusivity and patent expiration timeline.
- Without an itemized patent estate and confirmed FDA/Orange Book record, the patent-driven exclusivity and generic entry risk cannot be stated to an investment standard.
FAQs
- Is INTAL protected by patents in the US, and which patents are listed by FDA for the exact dosage form?
- What factors determine whether cromolyn sodium ophthalmic and inhalation products face generic switching differently?
- How do formulation differences (pH, preservatives, excipients) affect generic design-around for cromolyn sodium brands?
- What litigation timeline patterns typically delay generic entry for legacy inhaled or ophthalmic small molecules?
- What supply-chain events most often disrupt availability and pricing for mature branded allergy products?
References
No sources were cited because the prompt does not provide the specific INTAL product identifiers (dosage form, strength, applicant/labeler, jurisdiction scope) needed to produce accurate patent, Orange Book, litigation, or FDA status findings.
